This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tildrakizumab-ASMN, targeting the p19 subunit of interleukin-23 (IL23A). IL-23 is a heterodimeric cytokine that plays a critical role in inflammatory and immune responses by promoting the differentiation and survival of Th17 cells, which produce pro-inflammatory cytokines including IL-17. The IL-23/Th17 axis is implicated in the pathogenesis of various autoimmune and inflammatory conditions, particularly chronic plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease. Dysregulated IL-23 signaling contributes to sustained inflammation and tissue damage in these disorders.
Tildrakizumab-ASMN is an FDA-approved humanized IgG1κ monoclonal antibody that specifically binds to the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor and subsequent downstream signaling. This biosimilar antibody serves as a valuable research tool for investigating IL-23-mediated inflammatory pathways, studying mechanisms of autoimmune disease progression, evaluating therapeutic targets in dermatological and rheumatological conditions, and supporting preclinical studies in immunology and inflammation research.
Email: support@cusabio.com
Distributors Worldwide